In Brief This Week: Roka Bioscience, Hologic; Almac; Eurofins; Quest Diagnostics; Interleukin; and More | GenomeWeb

NEW YORK (GenomeWeb) – Roka Bioscience said in its Form 10-Q this week that it exercised an option to reduce the royalty rate it pays to Hologic. As a result, Roka paid $8 million and issued 865,063 shares of its common stock to Hologic subsequent to the closing of Roka's initial public offering last month. The option was exercisable if Roka raised less than $55 million in net proceeds from the IPO. Net proceeds from the offering were about $53.4 million, Roka said in its SEC document.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.